Podcasts about Morgans

Wrapping up a series of 5 episodes, Dr Jarvis finishes his discussion of mechanical CPR devices (MCDs) talking about papers from Utah, Vienna, Anchorage, and Cincinnati and then gives his take on how to interpret the literature and put it into practice.Papers discussed:1)    Youngquist ST, Ockerse P, Hartsell S, Stratford C, Taillac P: Mechanical chest compression devices are associated with poor neurological survival in a statewide registry: A propensity score analysis. Resuscitation. 2016;September;106:102–7.2)    Zeiner S, Sulzgruber P, Datler P, Keferböck M, Poppe M, Lobmeyr E, Van Tulder R, Zajicek A, Buchinger A, Polz K, et al.: Mechanical chest compression does not seem to improve outcome after out-of hospital cardiac arrest. A single center observational trial. Resuscitation. 2015;November;96:220–5.3)    Levy M, Yost D, Walker RG, Scheunemann E, Mendive SR: A quality improvement initiative to optimize use of a mechanical chest compression device within a high-performance CPR approach to out-of-hospital cardiac arrest resuscitation. Resuscitation. 2015;July;92:32–7.4)    Morgan S, Gray JJ, Sams W, Uhl K, Gundrum M, McMullan J: LUCAS Device Use Associated with Prolonged Pauses during Application and Long Chest Compression Intervals. Prehospital Emergency Care. 2023;March 9;28(1):114–7.5)    Grunau B, Reynolds J, Scheuermeyer F, Stenstom R, Stub D, Pennington S, Cheskes S, Ramanathan K, Christenson J: Relationship between Time-to-ROSC and Survival in Out-of-hospital Cardiac Arrest ECPR Candidates: When is the Best Time to Consider Transport to Hospital? Prehospital Emergency Care. 2016;September 2;20(5):615–22.  FAST25 | May 19-21, 2025 | Lexington, KY

The US stock market fell for the third day in a row on Friday – the 2nd worst day for US equities in 2025 due to tariffs expected this week and hotter than anticipated inflation numbers.

The US stock market fell for the second day in a row on Thursday after trading sideways for most of the session. Traders remained cautious ahead of Friday's release of the Fed's preferred inflation gauge. Dow fell -155-points to trade below 42,300 points. Shares of Goldman Sachs (-2.61%), 3M co (-2.78%) and NIVIDIA (-2.05%) each contributing to the decline, falling over >2.00%.

All three major U.S. stock indices snapped a three-day winning streak as an imminent tariff announcement from President Trump derailed the recovery from a month-long selloff - Dow fell -132.71-points or 0.31% lower. Nvidia Corp fell -5.74% amid concerns about possible new restrictions on the chipmaker's sales in China. Regulators in China have been discouraging the country's large technology companies from purchasing Nvidia's H20 chip - specifically designed to satisfy U.S. sanctions on exports - as it breaches energy-efficiency rules, the Financial Times reported, citing people with knowledge of the matter. Boeing Co fell -2.1% after a federal judge ordered the airplane maker to go to trial in June in a criminal case related to two 737 MAX crashes in 2018 and 2019. The Wall Street Journal reported Monday (24 March) that Boeing sought to withdraw an earlier agreement to plead guilty in the case that blamed it for deceiving regulators before the crashes. The broader S&P500 shed -1.1% and the biggest decline in almost 2 weeks. Consumer staples rose +1.42%, leading five of the eleven primary sectors higher. Information technology was the worst hit -down -2.46% and sat at the foot of the primary sector leaderboard followed by Communication services- down 2.04%

In this insightful interview, Michael Knox, Chief Economist at Morgans, discusses Australia's growing debt and current account deficit, as outlined in the 2025 federal budget. With projections showing a significant increase in debt over the next few years, Michael explores the implications for future generations and whether the government's economic strategies are sustainable. He also reflects on historical warnings from former Prime Minister Paul Keating about the risk of becoming a "banana republic." Tune in for a deep dive into Australia's financial outlook and the challenges ahead.

• US equity markets settled with modest gains, boosted by a late rally among large capitalisation technology names and shrugging off some weaker-than-expected consumer confidence data Dow inched +4-points higher. ‘Magnificent Seven' members Amazon.com Inc (up +1.21%) and Apple Inc (+1.37%), investment banks Goldman Sachs Group Inc (+1.01%) and JPMorgan Chase & Co (+1.24%) and Walt Disney Co (+1.43%) all climbed over >1%. Merck & Co fell -4.81% after the company announced a US$2B commitment for Oral Lipid-Lowering Drug from Chinese Biotech Jiangsu Hengrui.

Founded by Wes Maas with just one Bobcat and a tipper truck, the company has built a strong reputation and now operates across various segments, including Construction Materials, Civil Construction and Hire, Manufacturing and Equipment Sales, and Residential and Commercial Real Estate.

Should Ducko change the style of his face snake, we get Morgans reactions to the teams song selections for her birthing playlist and Jess wants to know if she's overreacting after something Angus said to her last night!Subscribe on LiSTNR: https://play.listnr.com/podcast/nick-jess-and-duckoSee omnystudio.com/listener for privacy information.

We work out where you do your best thinking, play a round of year of the song and the team give Ducko their suggestions for Morgans push playlist!Subscribe on LiSTNR: https://play.listnr.com/podcast/nick-jess-and-duckoSee omnystudio.com/listener for privacy information.

US equity markets kicked off the week with sharp gains, buoyed by news reports the Trump administration's plans for reciprocal tariffs will be more targeted than initially feared. Investors are also preparing for a busy week of data, including the Federal Reserve's preferred inflation gauge on Friday. The VIX fell to its lowest in more than a month.

US equity markets settled with modest gains on Friday (21 March) following a late-session rally, erasing earlier losses after comments from U.S. President Trump provided hope that previously announced tariffs expected to begin in early April may not be as burdensome as feared - Dow edged +32-points or +0.08% higher, with Boeing Co rising +3.06% after the Trump administration awarded the plane maker a contract to build the U.S. Air Force's most sophisticated fighter jet (to be called the F-47), beating out rival Lockheed Martin Corp (down -5.79%). While financial details were not disclosed, The Wall Street Journal estimated that research, development, and acquisition costs could exceed >US$50B. Nike Inc fell -5.42% and was the worst performing Dow component after posting its fiscal third quarter result after the close of the previous session and projected a sharper decline in fourth-quarter revenue than analysts had anticipated.

Is there a similarity between F1 driver Oscar Piastri and our very own Shy Guy? We find out if your relationship started with fast food and Morgans tasked Ducko in creating a push playlist and we need your help!Subscribe on LiSTNR: https://play.listnr.com/podcast/nick-jess-and-duckoSee omnystudio.com/listener for privacy information.

US equity market ticked lower on Thursday as uncertainty around the U.S. economy continued to weigh on equities, thwarting the market's attempts at recovery from a monthlong rout. The Dow Jones closed around the flatline -11.31 points, or 0.03%, closing at 41,953.32. The S&P 500 lost -12.40 points or 0.22%, to close at 5,662.89. The Nasdaq Composite dipped -59.16 points or 0.33% to 17,691.63. The Small-cap Russell 2000 continued the trend losing -0.65%.

US equity markets rallied on Wednesday, with the S&P 500 clawing back more of the rout since late February that took the benchmark briefly into correction territory.

Morgans AM - Wednesday, 19 March 2025 by Morgans Financial

US equity markets rose on Monday, building on their comeback from a four-week rout on Wall Street after mixed economic data and ahead of talks between U.S. President Donald Trump and Russian President Vladimir Putin aimed at ending the Ukraine war.

Submit your stock picks here: ausbiz.co/callpicksDavid Lane from Ord Minnett and Raymond Chan from Morgans go in-depth and stock specific on ‘the call.'JB Hi-Fi (JBH) Wesfarmers (WES)Qantas (QAN)CBA (CBA) Westpac (WBC)Mirvac Group (MGR) CSL (CSL) ResMed (RMD) BHP (BHP) Woodside (WDS)Stock of the day: Treasury Wine Estates (TWE) to listen go to https://ausbiz.co/STODGet your stock pick to the front of the queue by becoming an ausbiz contributor: https://ausbiz.co/contributorsAnd we'd love it if you could leave us a review below! Hosted on Acast. See acast.com/privacy for more information.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WQG865. CME/MOC/AAPA/IPCE credit will be available until March 14, 2026.Individualizing Prostate Cancer Management: Employing Evidence-Based Strategies to Impact Community Care Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WQG865. CME/MOC/AAPA/IPCE credit will be available until March 14, 2026.Individualizing Prostate Cancer Management: Employing Evidence-Based Strategies to Impact Community Care Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WQG865. CME/MOC/AAPA/IPCE credit will be available until March 14, 2026.Individualizing Prostate Cancer Management: Employing Evidence-Based Strategies to Impact Community Care Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WQG865. CME/MOC/AAPA/IPCE credit will be available until March 14, 2026.Individualizing Prostate Cancer Management: Employing Evidence-Based Strategies to Impact Community Care Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WQG865. CME/MOC/AAPA/IPCE credit will be available until March 14, 2026.Individualizing Prostate Cancer Management: Employing Evidence-Based Strategies to Impact Community Care Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WQG865. CME/MOC/AAPA/IPCE credit will be available until March 14, 2026.Individualizing Prostate Cancer Management: Employing Evidence-Based Strategies to Impact Community Care Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

US equity markets weaker on Wednesday, big tech continuing to hurt indices, with select Consumer names also being sold off. US PPI came in a touch below expectations, which followed a CPI print below expectations the day prior, but tariffs (and the threat of tariffs) were louder and seemed the focus of market moves. The Dow fell 537 points or -1.30%. Apple continued its negative trajectory, shares down another -3.36%, extending a string of recent losses on concerns over delayed Siri features and the impact of tariffs. The stock fell for the third-straight session after Apple on Friday reportedly pushed back the launch of certain Apple Intelligence features for Siri until 2026. The stock is -20% off its highs set in late December.

US equity markets mixed on Wednesday, select beaten up tech names in the green, while large Consumer Staples continued to pull back, as US annual inflation rate fell to 2.8% in February, below forecasts of 2.9%. The core rate, which excludes volatile food and energy prices, was 3.1% versus expectations of 3.2%.

Podcast 380 (12/3) met Bas en Carlo staat in het teken van passagiersvliegtuigen, imponerende Morgans, superieure caravantrekkers, een ballade-achtige Jingle, racende Capri's en andere gezelligheid. Ook de rally van Gijs van Lennep en de Franse ‘Flux Libre' tolpoorten (nee, niét gratis!) worden besproken. En dat alles binnen een uur. Enjoy.

Podcast 380 (12/3) met Bas en Carlo staat in het teken van passagiersvliegtuigen, imponerende Morgans, superieure caravantrekkers, een ballade-achtige Jingle, racende Capri’s en andere gezelligheid. Ook de rally van Gijs van Lennep en de Franse ‘Flux Libre’ tolpoorten (nee, niét gratis!) worden besproken. En dat alles binnen een uur. Enjoy. Word lid! Want wil je 100% bewezen Komjoenittie-lid blijven, dan moet je lid worden van de APK, de Alleen Petrolheads Komjoenittie. Lid worden kan via www.bnr.nl/apk. Je kan ook een mailtje sturen naar petrolheads@bnr.nl en dan helpt Jorn je verder. Aanmelden BNR Petrolheads Tourrit is zoals bekend op 6 april aanstaande. Inschrijven kan via www.bnr.nl/apk.

US equity markets were again weaker on Tuesday, tariffs (both actual and threatened) making investors skittish. The Dow fell 478 points or -1.14%.

US equity markets were again weaker on Monday, investors worried that tariff policy uncertainty would tip the economy into a recession, something President Donald Trump did not rule out over the weekend in an interview. 'Risk-off' sentiment can definitely be seen in US market trading. The Dow fell 890 points or -2.08%, the 30-stock index dragged down by Nvidia, Goldman Sachs and Apple, down -5.07%, 5%, and 4.85% respectively.

US equity markets advanced, recovering from steep losses earlier in the session following a lacklustre jobs report and after Federal Reserve Chair Jerome Powell said the economy remains in good shape. The Dow was up 222 points or 0.52%, the 30-stock index led by IBM (up 5.1%), and Verizon Communications (up 4.14%) leading the charge.

Hi Guys, welcome back to TV Reload. Thank you for clicking or downloading on today’s episode with Alana McClean… who is basically now a Real Housewife of Beverely Hills herself after receiving a like on social media from Dorit this week. We go deep on the 14th episodes of Beverely Hills season 14 which are called Hemlines and headlines and this could be the most different reaction Alana and I have had of the season and we will get into that. Plus guys if you want to score the eps too? Please hit us up on social media. We will discuss, the way in which Garcelle and Sutton have double standards… and maybe that happens when you have been on a show like this for as long as they have been. I will get Alana’s perspective on Morgans name coming up a fair bit and what she thinks at this stage. Has this relationship been an emotional affair or was this at one stage actually romantic. We will address the fact Sutton’s Mum couldn’t make the fashion show and why Sutton wouldn’t just pop her on a private plane. You are going to get plenty of chat on Dorit’s catch up with Garcelle. What we think of the modelling career trajectory of children of these housewives and of source we will unpack that tweet from Alana that Dorit popped a like on.. There is so much to talk about with so many inside revelations. So sit back and relax as we unpack the wonderful world of the RHOBH season 14!See omnystudio.com/listener for privacy information.

U.S. equity markets were down overnight as the market digests Trumps whipsawing tariff decisions. The Dow was down -0.92% to 42,612 points. Nvidia was the main drag, falling -5.52% after CFO Colette Kress stated it would take some time for them to meet demand for their Blackwell chips.

US equity markets advanced following two session of heavy losses as investors eyed a near term reprieve for the automotive sector from President Trump' tariff measures that may be a portent of further concessions - Dow rose +486-points or +1.14% Microsoft Corp (up +3.23%) and Caterpillar Inc (+3.59%) both rallied over >3% to be the leading performers in the 30-stock index.

Morgans AM - Wednesday, 5 March 2025 by Morgans Financial

US equity markets fell sharply, unwinding opening gains as President Trump said that tariffs against Mexico and Canada will go ahead as planned tonight AEST (and also signed an action to impose an additional 10% duty on China, according to an administration official), while investors also digested signs of a fresh spike in inflation pressures - Dow dropped -650-points or -1.48%. Nvidia Corp fell 8.81% to US$114.22 to be the worst performer in the 30-stock index overnight, with the stock falling into official correction territory after settling more than >20% below its record all-time closing high of US$149.43 set on 6 January. There were reports that Nvidia and Broadcom Inc (-6.05%) are testing Intel Corp's (-4.17%) chip manufacturing process. Separately, The Wall Street Journal reported on Sunday (2 March) that Chinese buyers were finding ways to buy Nvidia's chips despite President Trump's attempts to limit sales to Beijing. Elsewhere, Amazon.com Inc (down -3.42%), Caterpillar Inc (-3.46%) and Chevron Corp (-3.49%) all fell over >3%.

Benchmark US equity indices settled with solid gains on Friday (28 February) on heavy volume to close out a dreary February on a brighter note, with investors digesting the latest inflation figures that pushed US Treasury yields to fresh multi-month lows - Dow rose +601-points or +1.39%, with 26 of 30 index components advancing.

Wall Street trading got off to a negative start on Thursday following earnings from AI-darling Nvidia overnight and an update from Donald Trump regarding his proposed tariffs on a number of America's largest trading partners.

With the Australian reporting season just about coming to an end, Nvidia has been a big focus for investors on Wall Street. MARKET WRAP: ASX200: up 0.33%, 8,268 GOLD: $2,909 US/oz BITCOIN: $136,955 AUD Qantas shares jumped another 5.6% on the day to $9.39 – and has gained more than 80% over the last year. Medibank Private announced better retention of clients and fewer claims shares up just under 10% to $4.42 Ramsay Health Care shares up more than 6% to $36.18 Infratil lifted more than 2% to $9.72 after an increase in shareholding from some board members. Sequoia reported 137% lift in profit - shares jumped more than 3% to 44 ½ cents. Perpetual fell just under 10% after a disappointing reporting result and again confirming the takeover from private equity firm KKR was off the table. Mercury New Zealand shares down 7% to $5.40 Pro medicus fell more than 3% to $263.08 and CSL fell 1.7% to $260.29 And Wisetech global have had a busy week, but shares were sold down today down to $93.99. CURRENCY UPDATE: AUD/USD: 62.95 US cents AUD/GBP: 49.7 pence AUD/EUR: 60 Euro cents AUD/JPY: 94 Japanese yen AUD/NZD: 1.10 NZ dollars See omnystudio.com/listener for privacy information.

US equity markets were mixed again on Wednesday trading with The DOW falling 188 Points or -0.43% The broader S&P500 was virtually unchanged settling one point higher at 5,956 points.

US equity markets were mixed again on Tuesdays trading with The DOW up 159 Points or +0.37%. The broader S&P500 was negative losing 27 Points or 0.45% to settle at 5,955 points. And again, the Nasdaq was the worst performing index falling 260 points or -1.35% to 19,026 points. The Nasdaq's loss today pushing it to a 4-day loss of around 5% the most since Sept 2024

The S&P 500 and Nasdaq extended last week's sharp declines, led by fresh falls for large capitalisation technology names - Dow edged +33-points or +0.55%, steadying after posting its worst weekly performance since the stretch ended 25 October last year last week (down -2.51%) and wiping out all its post presidential inauguration gains.

US equity markets retreated heavily on Friday The DOW down 750 Points or -1.7% amid reports of increased volatility and a potential correction sited by Goldman Sacs as being related to some 2.7 Trillion in derivatives that are set to expire. Only the consumer staples sector was positive during the session up 1% whilst Consumer discretionary was the worst sector down 2.77%. The Energy, IT and Industrials sectors all falling 2% or more.

Stocks declined on Thursday after two consecutive record highs for the S&P 500, as investors sold off popular stocks following Walmart's cautious forecast, raising concerns about the broader economic outlook. It was red across the board with all four major US indices closing down.

For our month of romcoms, we revisit a late era Hugh Grant flick in which he pairs up with Sarah Jessica Parker.  Basically what City Slickers would be like if you replaced Billy Crystal with Hugh Grant and both Daniel Stern and Bruno Kirby with Sarah Jessica Parker.  And Jack Palance with Sam Elliott, which is probably the nearest to a 1 to 1 ratio.

Both the Australian sharemarket and dollar were hit hard after the US confirmed import tariffs will be applied on Mexican, Canadian and Chinese products from Feburary 4th, so SBS Finance Editor Ricardo Gonçalves takes a closer look at the implications for the sharemarket and for Australia with Raymond Chan from Morgans; Rhayna Bosch speaks with Tim Lawless from CoreLogic on the year ahead in property.

Get ready for one of the most inspiring episodes yet with the legendary lad Morgan Mitchell. Born deaf, Morgan's journey to becoming a professional rugby player was never going to be easy. Although he was an absolute beast on the rugby field from a young age, he was always told that he would never be able to play professional rugby. Thankfully the man who is known for his stubbornness was not having a bar of it and did manage to debut for his beloved Southland stags in 2014. He has since gone on to play over 50 games for the Stags as well as playing overseas with the Toronto ArrowsKamaishi Seawaves and Houston SaberCats.This story is a great one about never giving up on your dreams and a great reminder of some of the obstacles you can overcome when you put your mind to it. Morgy is such a champion, a very funny man and like his brother Brayden can tell a hell of a yarn. It was an honour to be the first podcast to share Morgans journey and if you enjoy this episode then I ask if you could please like the video and let me know what you enjoyed about this one in the comments.EXCLUSIVE NordVPN Deal ➼ https://nordvpn.com/whatalad Try it risk-free now with a 30-day money-back guarantee Hosted on Acast. See acast.com/privacy for more information.

It's a brave new world Dear Listeners. Your usual trio of numpties Andy, Ant and Dun guide you through the last week in QPR, New York, Executive orders and the New World Order. Thank god for the football... - We're Ninth! We're in Single digits! (until tomorrow) - 2 away games, 6 points, a ton of miles - The Contract kids, Lloyd and Kolli make the away fans Jolly - Why is Plymouth's keeper so bloody good against us - A great week for the Morgans, Keiran & Fox - A varied week for our Loanees. Edwards looks a steal, Ashby a sub-par sub - Koki's not hokey - Saito's stunning first goal for the club - We're 9th! Single digits! - A 'this week in New Yorking' x 'Democracy Manifest' Mash-up - The Gulf of America, America America and Johnny Childish - NFL stuff. New York happy: Buffalo advance to take on the Chiefs. New Jersey not happy: Saquon lifts the Eagles to an NFC East match up vs The Commanders - Dun doesn't do buses, even if they're quicker - Andy's a scale-model citizen - Ant's low blood pressure TV guide - Seann Walsh visits the Football Factory: Stand-up comedian and a stand-up guy - A gritty tale from Scunthorpe - Sheffield Wednesday up next. Will QPR have an 'owler? - QPR NYC's favorite New York Bands do South x South West London. - 'Fix your hearts or die' - RIP David Lynch. Thank you for the damn fine Cherry Pie. If you feel so inclined, hit us up with that sweet sweet 5 star review! All feedback most welcome.

Dr. Susan Fay is an internationally-known speaker, clinician, consultant, and author of Sacred Spaces -Communion with the horse through Science and Spirit. She has an educational background in psychology, and environmental science, but believes she learned the most valuable life lessons from her horses. Susan acquired numerous local, national, and world championships on her beloved Morgans, but retired from the show ring to devote her time to teaching. Her passion is to introduce people to psychological and energetic principles that allow them to BE in this world in a more meaningful way, and to experience communion with their horses, dogs, and other animals.

We know the literature on mechanical CPR devices on mortality in out of hospital cardiac arrest (we DO know this literature, right?), but what about in-hospital arrest? Dr. Jarvis reviews a recent paper that uses the AHA Get With The Guidelines - Resuscitation registry to assess the association between MCDs and mortality. Citations1. Crowley C, Salciccioli J, Wang W, Tamura T, Kim EY, Moskowitz A: The association between mechanical CPR and outcomes from in-hospital cardiac arrest: An observational cohort study. Resuscitation. 2024;May 1;198.2. Rubertsson S, Lindgren E, Smekal D, Östlund O, Silfverstolpe J, Lichtveld RA, Boomars R, Ahlstedt B, Skoog G, Kastberg R, et al.: Mechanical Chest Compressions and Simultaneous Defibrillation vs Conventional Cardiopulmonary Resuscitation in Out-of-Hospital Cardiac Arrest: The LINC Randomized Trial. JAMA. 2014;January 1;311(1):53–613. Hardig BM, Lindgren E, Östlund O, Herlitz J, Karlsten R, Rubertsson S: Outcome among VF/VT patients in the LINC (LUCAS IN cardiac arrest) trial—A randomised, controlled trial. Resuscitation. 2017;June;115:155–62.4.  Perkins GD, Lall R, Quinn T, Deakin CD, Cooke MW, Horton J, Lamb SE, Slowther A-M, Woollard M, Carson A, et al.: Mechanical versus manual chest compression for out-of-hospital cardiac arrest (PARAMEDIC): a pragmatic, cluster randomised controlled trial. The Lancet. 2015;385(9972):947–55.5.  Wik L, Olsen J-A, Persse D, Sterz F, Lozano M, Brouwer MA, Westfall M, Souders CM, Malzer R, Van Grunsven PM, et al.: Manual vs. integrated automatic load-distributing band CPR with equal survival after out of hospital cardiac arrest. The randomized CIRC trial. Resuscitation. 2014;June;85(6):741–8.6. Bonnes JL, Brouwer MA, Navarese EP, Verhaert DVM, Verheugt FWA, Smeets JLRM, Boer M-J de: Manual Cardiopulmonary Resuscitation Versus CPR Including a Mechanical Chest Compression Device in Out-of-Hospital Cardiac Arrest: A Comprehensive Meta-analysis From Randomized and Observational Studies. Ann Emerg Med Annals of emergency medicine. 2016;67(3):349-360.e3.7. Gonzales L, Oyler BK, Hayes JL, Escott ME, Cabanas JG, Hinchey PR, Brown LH: Out-of-hospital cardiac arrest outcomes with “pit crew” resuscitation and scripted initiation of mechanical CPR. The American Journal of Emergency Medicine. 2019;May;37(5):913–20.8. Koster RW, Beenen LF, Van Der Boom EB, Spijkerboer AM, Tepaske R, Van Der Wal AC, Beesems SG, Tijssen JG: Safety of mechanical chest compression devices AutoPulse and LUCAS in cardiac arrest: a randomized clinical trial for non-inferiority. European Heart Journal. 2017;October 21;38(40):3006–13.9. Primi R, Bendotti S, Currao A, Sechi GM, Marconi G, Pamploni G, Panni G, Sgotti D, Zorzi E, Cazzaniga M, et al.: Use of Mechanical Chest Compression for Resuscitation in Out-Of-Hospital Cardiac Arrest—Device Matters: A Propensity-Score-Based Match Analysis. JCM. 2023;June 30;12(13):4429.10. Youngquist ST, Ockerse P, Hartsell S, Stratford C, Taillac P: Mechanical chest compression devices are associated with poor neurological survival in a statewide registry: A propensity score analysis. Resuscitation. 2016;September;106:102–7.11.  S, Sulzgruber P, Datler P, Keferböck M, Poppe M, Lobmeyr E, Van Tulder R, Zajicek A, Buchinger A, Polz K, et al.: Mechanical chest compression does not seem to improve outcome after out-of hospital cardiac arrest. A single center observational trial. Resuscitation. 2015;November;96:220–5. 12. Morgan S, Gray JJ, Sams W, Uhl K, Gundrum M, McMullan J: LUCAS Device Use Associated with Prolonged Pauses during Application and Long Chest Compression Intervals. Prehospital Emergency Care. doi: 10.1080/10903127.2023.2183294 (Epub ahead of print).13.  Levy M, Yost D, Walker RG, Scheunemann E, Mendive SR: A quality improvement initiative to optimize use of a mechanical chest compression device within a high-performance CPR approach to out-of-hospital cardiac arrest resuscitation. Resuscitation. 2015;July;92:32–7.14.  Li H, Wang D, Yu Y, Zhao X, Jing X: Mechanical versus manual chest compressions for cardiac arrest: a systematic review and meta-analysis. Scand J Trauma Resusc Emerg Med. 2016;December;24(1):10.15.  Sheraton M, Columbus J, Surani S, Chopra R, Kashyap R: Effectiveness of Mechanical Chest Compression Devices over Manual Cardiopulmonary Resuscitation: A Systematic Review with Meta-analysis and Trial Sequential Analysis. WestJEM. 2021;July 19;22(4):810–9.16.  Wang PL, Brooks SC: Mechanical versus manual chest compressions for cardiac arrest. Cochrane Database Syst Rev The Cochrane database of systematic reviews. 2018;20;8:CD007260.17.  Zhu N, Chen Q, Jiang Z, Liao F, Kou B, Tang H, Zhou M: A meta-analysis of the resuscitative effects of mechanical and manual chest compression in out-of-hospital cardiac arrest patients. Crit Care. 2019;December;23(1):100.

With shoppers set to spend big over the festive period despite higher cost of living pressures, SBS Finance Editor Ricardo Gonçalves speaks with Sally Tindall from Canstar about what credit card users need to know about interest free day periods, Harry Murphy Cruise from Moody's Analytics goes through today's release of the RBA's December board meeting minutes, and Dianne Colledge from Morgans looks through her 2025 crystal ball.